Literature DB >> 22262248

The association of cardiovascular disease and metabolic syndrome with nephrolithiasis.

Jessica N Lange1, Patrick W Mufarrij, Kyle D Wood, Ross P Holmes, Dean G Assimos.   

Abstract

PURPOSE OF REVIEW: This review describes the relationship between nephrolithiasis, vascular disease and metabolic syndrome. RECENT
FINDINGS: There is increasing evidence that kidney stone formation is associated with a number of systemic problems including cardiovascular disease, metabolic syndrome and its components. Some of these associations are bidirectional. The reasons for these associations are not totally clear, but potential factors include metabolic responses associated with these disorders that promote a stone forming milieu in urine, environmental factors such as diet, oxidative stress and inflammation and molecular changes impacting the transport of certain analytes in urine.
SUMMARY: Urologists need to be cognizant of these associations as they may be able to contribute to an early diagnosis of a significant medical problem, or provide counseling to patients to prevent their occurrence.

Entities:  

Mesh:

Year:  2012        PMID: 22262248     DOI: 10.1097/MOU.0b013e32834fc31f

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  12 in total

1.  Vascular calcification and bone mineral density in recurrent kidney stone formers.

Authors:  Linda Shavit; Daniela Girfoglio; Vivek Vijay; David Goldsmith; Pietro Manuel Ferraro; Shabbir H Moochhala; Robert Unwin
Journal:  Clin J Am Soc Nephrol       Date:  2015-01-29       Impact factor: 8.237

Review 2.  Urolithiasis: evaluation, dietary factors, and medical management: an update of the 2014 SIU-ICUD international consultation on stone disease.

Authors:  Helene Jung; Sero Andonian; Dean Assimos; Timothy Averch; Petrisor Geavlete; Yasuo Kohjimoto; Andreas Neisius; Joe Philip; Alberto Saita; Hemendra Shah; Palle Jörn Osther
Journal:  World J Urol       Date:  2017-02-03       Impact factor: 4.226

3.  The Occurrence of Nephrolithiasis in Gout Patients: A Longitudinal Follow-Up Study Using a National Health Screening Cohort.

Authors:  So Young Kim; Dae Myoung Yoo; Ji Hee Kim; Mi Jung Kwon; Joo-Hee Kim; Jung Woo Lee; Woo Jin Bang; Hyo Geun Choi
Journal:  Life (Basel)       Date:  2022-04-28

Review 4.  Nephrolithiasis and hypertension: possible links and clinical implications.

Authors:  Adamasco Cupisti; Claudia D'Alessandro; Sara Samoni; Mario Meola; Maria Francesca Egidi
Journal:  J Nephrol       Date:  2014-02-28       Impact factor: 3.902

5.  Metabolic Syndrome and Nephrolithiasis Risk: Should the Medical Management of Nephrolithiasis Include the Treatment of Metabolic Syndrome?

Authors:  John Michael DiBianco; T W Jarrett; Patrick Mufarrij
Journal:  Rev Urol       Date:  2015

6.  Evidence for a distinct gut microbiome in kidney stone formers compared to non-stone formers.

Authors:  Joshua M Stern; Saman Moazami; Yunping Qiu; Irwin Kurland; Zigui Chen; Ilir Agalliu; Robert Burk; Kelvin P Davies
Journal:  Urolithiasis       Date:  2016-04-26       Impact factor: 3.436

Review 7.  Metabolic syndrome and nephrolithiasis.

Authors:  Krishna Ramaswamy; Ojas Shah
Journal:  Transl Androl Urol       Date:  2014-09

8.  Predictive value of preoperative inflammatory response biomarkers for metabolic syndrome and post-PCNL systemic inflammatory response syndrome in patients with nephrolithiasis.

Authors:  Kun Tang; Haoran Liu; Kehua Jiang; Tao Ye; Libin Yan; Peijun Liu; Ding Xia; Zhiqiang Chen; Hua Xu; Zhangqun Ye
Journal:  Oncotarget       Date:  2017-08-18

Review 9.  The influence of metabolic syndrome and its components on the development of nephrolithiasis.

Authors:  Carter Boyd; Kyle Wood; Dustin Whitaker; Dean G Assimos
Journal:  Asian J Urol       Date:  2018-06-08

10.  The Risk of Nephrolithiasis Among Patients With Ankylosing Spondylitis: a Population-Based Cohort Study.

Authors:  Mu Tsun Shih; Shou Hung Tang; Tai Lung Cha; Sheng Tang Wu; Jen Huai Chiang; Wen Chi Chen
Journal:  Arch Rheumatol       Date:  2016-08-01       Impact factor: 1.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.